# Method Development for Single-Cell Multi-omics

> **NIH NIH R35** · CINCINNATI CHILDRENS HOSP MED CTR · 2022 · $397,500

## Abstract

Abstract.
Epigenetic modifications, including DNA methylation, histone modifications, and three-dimensional (3D) genome
topology, combine with genetic content to determine mammalian transcriptional factor (TF) binding and thus,
gene regulation. Gene activation or repression potential, however, cannot be entirely predicted by looking at a
single measurement. Accurate predictive models require multiple measurements to be measured simultaneously.
At present, we are limited by the number of simultaneous measurements that we can perform in a single cell. In
addition, the interactions between different epigenetic marks and their effects on gene expression are revealed
either in homogenous cultured cells or bulk tissues that average the readout. The study of interactions between
different cell-type-specific epigenetic marks and gene expression in heterogeneous tissues at the single cell level
is still in its infancy. Progress made during the last decade addressed the heterogeneity of individual cells in
terms of gene expression and epigenetic marks at different primary mammalian tissues using single-cell
sequencing techniques, such as single-cell RNA-seq. Recently, we and others developed several technologies
to simultaneously capture multiple measurements in the same assay (multi-omics techniques) and extended
them to the single-cell level. However, current single-cell multi-omics technology can only capture a couple of
measurements, which limits our ability to fully understand the integration of epigenetic marks, genomics, and
their effects on gene expression. Importantly, adding an additional “omics” assay in the existing experimental
protocol is not a simple combination of two existing assays. On the contrary, the add-on assay will often require
the re-design of the whole experimental protocol and/or the development of a new computational method. Adding
additional “omics” assay to the same experiment or single cell will significantly expand our current knowledge on
gene regulation. This is not achievable by joining separate mono-omics experiments in aliquots of the same
sample. Given these challenges, significance, and my unique multidisciplinary academic training, my long-term
goal is to develop high-throughput experimental assays and computational methods to understand gene
regulation by integrating the multi-omics information from the same assay or single-cells. In this proposal, we
will develop a combined experimental assay and computational approach to characterize multiple high-quality
cell-type-specific epigenomic and transcriptomic maps in the same assay and single cells. We will further develop
an integrated assay to characterize the regulatory role of genetic variants on gene expression through multiple
intermediate epigenomic activities in the same single cells. These approaches will eventually allow us to address
the fundamental questions for the interpretations of genetic variants and therefore bridge the gaps between
genetic and phenot...

## Key facts

- **NIH application ID:** 10499427
- **Project number:** 1R35GM147283-01
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** Yaping Liu
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $397,500
- **Award type:** 1
- **Project period:** 2022-08-01 → 2027-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10499427

## Citation

> US National Institutes of Health, RePORTER application 10499427, Method Development for Single-Cell Multi-omics (1R35GM147283-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10499427. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*